Mangoceuticals, End Period Cash Flow from 2010 to 2025
| MGRX Stock | 2.47 0.34 12.10% |
End Period Cash Flow | First Reported 2010-12-31 | Previous Quarter 58.7 K | Current Value 55.7 K | Quarterly Volatility 234 K |
Check Mangoceuticals, Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mangoceuticals, Common's main balance sheet or income statement drivers, such as Depreciation And Amortization of 768 K, Interest Expense of 14.4 K or Selling General Administrative of 3.2 M, as well as many indicators such as Price To Sales Ratio of 9.61, Dividend Yield of 0.14 or PTB Ratio of 0.36. Mangoceuticals, financial statements analysis is a perfect complement when working with Mangoceuticals, Common Valuation or Volatility modules.
Mangoceuticals, | End Period Cash Flow |
Latest Mangoceuticals, Common's End Period Cash Flow Growth Pattern
Below is the plot of the End Period Cash Flow of Mangoceuticals, Common Stock over the last few years. It is Mangoceuticals, Common's End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mangoceuticals, Common's overall financial position and show how it may be relating to other accounts over time.
| End Period Cash Flow | 10 Years Trend |
|
End Period Cash Flow |
| Timeline |
Mangoceuticals, End Period Cash Flow Regression Statistics
| Arithmetic Mean | 112,927 | |
| Geometric Mean | 38,989 | |
| Coefficient Of Variation | 207.17 | |
| Mean Deviation | 149,501 | |
| Median | 22,550 | |
| Standard Deviation | 233,956 | |
| Sample Variance | 54.7B | |
| Range | 716.5K | |
| R-Value | 0.44 | |
| Mean Square Error | 47.2B | |
| R-Squared | 0.20 | |
| Significance | 0.09 | |
| Slope | 21,751 | |
| Total Sum of Squares | 821B |
Mangoceuticals, End Period Cash Flow History
About Mangoceuticals, Common Financial Statements
Mangoceuticals, Common investors use historical fundamental indicators, such as Mangoceuticals, Common's End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Mangoceuticals, Common. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| End Period Cash Flow | 58.7 K | 55.7 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Mangoceuticals, Stock Analysis
When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.